斯帕森坦治疗IgA肾病:一项随机双盲活性对照临床试验的预设中期分析
PROTECT是一项在18个国家134个临床中心开展的国际随机双盲活性对照3期试验,纳入404例经活检证实且已最大化RAS抑制剂治疗的成人IgA肾病患者,1:1随机接受斯帕森坦400 mg每日一次或厄贝沙坦300 mg每日一次。第36周时,斯帕森坦组尿蛋白肌酐比较基线几何最小二乘均值下降49.8%,厄贝沙坦组下降15.1%,组间相对降低41%(LS均值比=0.59;95%CI 0.51-0.69;p<0.0001)。两组治疗中出现的不良事件相似,未发生重度水肿、心力衰竭、肝毒性或水肿相关停药。
要点
- 斯帕森坦组第36周尿蛋白肌酐比较基线下降49.8%,厄贝沙坦组下降15.1%。
- 组间相对降低41%(LS均值比=0.59;95%CI 0.51-0.69;p<0.0001)。
- 斯帕森坦与厄贝沙坦的治疗中出现的不良事件相似,未发生重度水肿、心力衰竭、肝毒性或水肿相关停药。
核心结论
- 在成人IgA肾病患者中,与厄贝沙坦相比,斯帕森坦每日一次治疗可产生有意义的蛋白尿下降,且安全性相似。
- 完成2年双盲期后的后续分析将显示这些有益效应是否转化为斯帕森坦的长期肾脏保护潜力。
研究设计与样本
- PROTECT为国际、随机、双盲、活性对照研究,在18个国家的134个临床实践中心开展。
- 研究纳入年龄≥18岁、经活检证实IgA肾病且尽管已最大化肾素-血管紧张素系统抑制剂治疗至少12周、蛋白尿仍≥1.0 g/天的成人。
- 参与者按1:1随机接受斯帕森坦400 mg每日一次或厄贝沙坦300 mg每日一次,按筛选时估算肾小球滤过率(30至<60 mL/min per 1.73 m2和≥60 mL/min per 1.73 m2)及筛选时尿蛋白排泄(≤1.75 g/天和>1.75 g/天)分层。
- 主要疗效终点为基于24小时尿样的尿蛋白肌酐比从基线至第36周的变化,采用混合模型重复测量评估;所有终点在至少接受一剂随机治疗的全部参与者中分析。
- 2018年12月20日至2021年5月26日期间,404例参与者被随机分配至斯帕森坦组(n=202)或厄贝沙坦组(n=202)并接受治疗。
主要发现
- 第36周时,尿蛋白肌酐比较基线的几何最小二乘均值百分比变化在斯帕森坦组为-49.8%,在厄贝沙坦组为-15.1%,组间相对降低41%(LS均值比=0.59;95%CI 0.51-0.69;p<0.0001)。
- 斯帕森坦的治疗中出现的不良事件与厄贝沙坦相似。
- 未发生重度水肿、心力衰竭、肝毒性或水肿相关停药。
- 斯帕森坦组与厄贝沙坦组的体重自基线变化无差异。
关键数值与推荐
- 主要疗效终点:第36周尿蛋白肌酐比较基线变化,斯帕森坦组-49.8% vs 厄贝沙坦组-15.1%,组间相对降低41%(LS均值比=0.59;95%CI 0.51-0.69;p<0.0001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文为预设中期分析,研究仍在进行中。
- 未来完成2年双盲期后的分析将显示这些有益效应是否转化为斯帕森坦的长期肾脏保护潜力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sparsentan is a novel, non-immunosuppressive, single-molecule, dual endothelin and angiotensin receptor antagonist being examined in an ongoing phase 3 trial in adults with IgA nephropathy. We report the prespecified interim analysis of the primary proteinuria efficacy endpoint, and safety. METHODS: PROTECT is an international, randomised, double-blind, active-controlled study, being conducted in 134 clinical practice sites in 18 countries. The study examines sparsentan versus irbesartan in adults (aged ≥18 years) with biopsy-proven IgA nephropathy and proteinuria of 1·0 g/day or higher despite maximised renin-angiotensin system inhibitor treatment for at least 12 weeks. Participants were randomly assigned in a 1:1 ratio to receive sparsentan 400 mg once daily or irbesartan 300 mg once daily, stratified by estimated glomerular filtration rate at screening (30 to <60 mL/min per 1·73 m2 and ≥60 mL/min per 1·73 m2) and urine protein excretion at screening (≤1·75 g/day and >1·75 g/day). The primary efficacy endpoint was change from baseline to week 36 in urine protein-creatinine ratio based on a 24-h urine sample, assessed using mixed model repeated measures. Treatment-emergent adverse events (TEAEs) were safety endpoints. All endpoints were examined in all participants who received at least one dose of randomised treatment. The study is ongoing and is registered with ClinicalTrials.gov, NCT03762850. FINDINGS: Between Dec 20, 2018, and May 26, 2021, 404 participants were randomly assigned to sparsentan (n=202) or irbesartan (n=202) and received treatment. At week 36, the geometric least squares mean percent change from baseline in urine protein-creatinine ratio was statistically significantly greater in the sparsentan group (-49·8%) than the irbesartan group (-15·1%), resulting in a between-group relative reduction of 41% (least squares mean ratio=0·59; 95% CI 0·51-0·69; p<0·0001). TEAEs with sparsentan were similar to irbesartan. There were no cases of severe oedema, heart failure, hepatotoxicity, or oedema-related discontinuations. Bodyweight changes from baseline were not different between the sparsentan and irbesartan groups. INTERPRETATION: Once-daily treatment with sparsentan produced meaningful reduction in proteinuria compared with irbesartan in adults with IgA nephropathy. Safety of sparsentan was similar to irbesartan. Future analyses after completion of the 2-year double-blind period will show whether these beneficial effects translate into a long-term nephroprotective potential of sparsentan. FUNDING: Travere Therapeutics.
引用
- Heerspink HJL, Radhakrishnan J, Alpers CE, et al. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. Lancet. 2023. PMID: 37015244. doi:10.1016/S0140-6736(23)00569-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。